ClinicalTrials.gg
RecruitingNCT06680323ExpoMelUpdated Nov 8, 2024

Identification of Risk Factors, Exposomics and Genetic Susceptibility of Melanoma in Children, Adolescents and Young Adults

An observational study in Melanoma, Spitzoid Melanoma and Congenital Nevi, sponsored by University Hospital Tuebingen. Recruiting at 6 sites in 5 countries. Open to participants aged Up to 30 Years. Per ClinicalTrials.gov, last updated 2024-11-08.

Sponsored by University Hospital Tuebingen · Observational

How we know

From the registry’s dates

  • Primary completion was expected by May 2025, 1 year 5 months ago, but the record still lists the study as recruiting.
  • Started Jan 2024; still recruiting 2 years 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
200
Ages
Up to 30 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 15 studies in Melanoma by University Hospital Tuebingen — 1 open to participants now, 1 under way, none of them phase 3. Melanoma · University Hospital Tuebingen.

Started
2024
the only one that year
Observational
2 of 15
1 open now
Registered
15th of 15
by date

Among the 15 studies in Melanoma by University Hospital Tuebingen, this one is the only one that started in 2024, is one of 2 observational ones, and was the 15th registered.

Melanoma

3,374 studies on the registry are indexed under Melanoma; 579 are open to participants now.

Browse Melanoma studies →

Open to participants now

1 of the 15 studies in Melanoma by University Hospital Tuebingen is open now, in 5 countries.

By country, each count listing its studies:

Where they have run

Who these studies take

Of the 467 Melanoma studies recruiting now, 379 (81%) set no upper age limit and 49 (10%) stop at 75 or younger; 47 take children under 18; 29 take healthy volunteers.

This study: Up to 30 Years · all sexes.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies in Melanoma by University Hospital Tuebingen, or all of them as a file.
02

Study summary

The primary objective of this study is the identification of environmental and genetic factors involved in the risk and progression of melanoma in children, adolescents and young adults (CAYA). The secondary objectives are to generate a model integrating the genetic and environmental factors to estimate the risk of developing melanoma and improve the primary prevention of melanoma through evidence-based interpretation of environmental risk.

Read the detailed description

By retrieving data from several epidemiological and clinical registries across Europe it is aimed to integrate and maximize efforts in order to create a large dataset that serves for a comprehensive analysis of genetic and environmental factors influencing the etiology of melanoma in CAYA. The data will be combined with exposome information about climate and pollution for the development of a weighted risk score. Furthermore, germline high risk mutations and germline low-medium risk variants will be analyzed. Genome and transcriptome sequencing of blood and in selected cases tumour will provide the most comprehensive data to create a polygenic risk score for CAYA melanoma. Transcriptome data will help to identify and characterize the effect of variants of unknown significance in coding, intronic as well as regulatory regions. Tumour sequencing can provide additional information on functional relevance of variants, e.g. secondary hits in tumour tissue or second hits in tumour suppressor genes. Such identification will be highly advantageous to design prevention strategies for melanoma development in CAYA.

03

Conditions studied

  • Melanoma
  • Spitzoid Melanoma
  • Congenital Nevi

Keywords

  • etiology
  • melanoma
  • children
  • adolescents
  • young adults
  • genetic predisposition
  • epidemiology
  • exposomes
04

Who can participate

Ages eligible
Up to 30 Years
Sexes eligible
All
Sampling method
Non-probability sample

Study population

Due to its registry-based retrospective study, no formal recruitment of patients will occur in ExpoMel. Data and samples will be obtained from the following registries and associated biobanks:

  • Catalonia Melanoma Network through Hospital Clinic Barcelona
  • The German Registry for Rare Pediatric Tumours (STEP) of the German Society for Pediatric Oncology and Hematology
  • Swedish Melanoma Registry (SweMR) through Karolinska Institute
  • Public Pathology Database of the Netherlands (PALGA) through Princess Maxima Center for Children OncologyCentral Registry Malignant Melanoma of the German Dermatological Society (CMMR)
  • Polish Pediatric Rare Tumor Study group and selected Eastern/Southern Europe countries cooperating within the European Cooperative Study Group for Pediatric Rare Tumors (EXPERT) through the Medical University Gdansk

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • confirmed melanoma
  • age until 30 years old

Exclusion criteria

Exclusion Criteria:

  • no available biological material
  • no signed
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
200 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • Classic melanoma

    Classic malignant melanoma under the age of 30 years For patients with available biospecimen, the germline genome, transcriptome and in selected cases tumour normal exomes will be sequenced.

  • Spitzoid melanoma

    Spitzoid melanoma under the age of 30 years For patients with available biospecimen, the germline genome, transcriptome and in selected cases tumour normal exomes will be sequenced.

  • Other melanoma

    Other melanoma as melanoma on congenital nevi under the age of 30 years For patients with available biospecimen, the germline genome, transcriptome and in selected cases tumour normal exomes will be sequenced.

06

What researchers measure

Primary outcomes

  1. Identification of environmental and genetic factors involved in the risk and progression of melanoma in children, adolescents and young adults (CAYA)

    By retrieving data from several epidemiological and clinical registries across Europe we aim to create a large dataset that serves for a comprehensive analysis of genetic and environmental factors influencing the etiology of melanoma in CAYA. Data on climate variables such as surface temperature, solar radiation, and air pollutants will be collected from ground-based instruments, such as air quality monitoring stations, and satellites and reanalysis data from the Copernicus Atmosphere Monitoring Service (CAMS). Data analysis from genome sequencing will be done using established bioinformatic pipelines and combined with exposome information about climate and pollution for the development of a weighted risk score.

    Time frame: 01.01.2024 - 30.11.2025

Secondary outcomes

  1. Generating a polygenic risk score for melanoma in CAYA by using the Lindeman-Merenda-Gold (LMG) method

    Genome and transcriptome sequencing of blood and in selected cases tumour will provide the most comprehensive data to create a polygenic risk score for melanoma in CAYA. We will develop a weighted risk score for each environmental factor, which comprises the effects of several variables measuring the respective risk factor. Additionally, a weighted risk score for the epigenetic variables will be build. To estimate the relative contribution of environmental and epigenetic factors we will calculate the relative importance (proportion of explained variance) of the weighted risk scores in an ordinary linear regression model using the Lindeman-Merenda-Gold (LMG) method.

    Time frame: 01.06.2024 - 31.05.2026

  2. Prevention strategies for melanoma development in CAYA

    The detected risk factors and determinants will be used by health professionals to update clinical guidelines for prevention, screening and early detection of melanoma in CAYA. Health care system strategies will be implemented in European countries overcoming current gaps in European countries on prevention and diagnosis of melanoma in CAYA. The success will be measured by incidence rates of melanoma.

    Time frame: 01.06.2025 - 30.09.2026

07

Study locations

3 of 6 sites recruiting
  • Leibniz Research Institute for Environmental Medicine
    Düsseldorf, 40225, Germany
    Active, not recruiting

    Not enrolling at this site.

  • University of Florence
    Florence, 50121, Italy
    Active, not recruiting

    Not enrolling at this site.

  • Istituto Nazionale del Tumori
    Milan, 20133, Italy
    Active, not recruiting

    Not enrolling at this site.

  • Medical University of Gdánsk
    Gdańsk, 80-210, Poland
    Recruiting
    • Ewa Bien, MD, PhD · Contact
  • Hospital Clínic de Barcelona
    Barcelona, 08036, Spain
    Recruiting
    • Susana Puig Sardá, MD, PhD · Contact
  • Karolinska Institute
    Solna, 17177, Sweden
    Recruiting
    • Hildur Helgadottir, MD · Contact
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jan 2024 (actual). Primary completion is estimated for May 2025, 16 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 25, 2024
First posted
Nov 8, 2024
StartActual
Jan 1, 2024
Primary completionEst.
May 31, 2025
CompletionEst.
May 31, 2026
Last update
Nov 8, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 8, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06680323
Collaborators
Hospital Clinic of Barcelona, University Of Perugia, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Karolinska University Hospital, Leibniz Research Institute for Environmental Medicine Düsseldorf, Princess Maxima Center for Pediatric Oncology, Medical University of Gdansk
Responsible party
Sponsor
First posted
Nov 8, 2024
Start date
Jan 1, 2024
Primary completion
May 31, 2025 (estimated)
Completion
May 31, 2026 (estimated)
Last update
Nov 8, 2024

Study contacts

Ines B Brecht, MD, PhD
Contact
ines.brecht@med.uni-tuebingen.de
+49707183773
Christopher Schroeder, MD
Contact
christopher.schroeder@med.uni-tuebingen.de

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion